- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07633938
The Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial
8. Juni 2026 aktualisiert von: Zhongshan Ophthalmic Center, Sun Yat-sen University
This study aims to conduct a randomized controlled clinical trial to compare the efficacy of a new type of massage device - eyelid support plate and glass rod assisted eyelid massage in improving MGD related dry eye symptoms, and evaluate the comfort and efficiency of both treatments, providing evidence-based support for clinical work
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Geschätzt)
142
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Qi Fu
- Telefonnummer: 86+66619334
- E-Mail: fuqi@gzzoc.com
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Zhongshan Ophthalmology Center, Sun Yat sen University
-
Kontakt:
- Bishan Tian
- Telefonnummer: 86+66619334
- E-Mail: tianbishan@gzzoc.com
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Voluntarily participate and sign an informed consent form;
- Age range: 18 to 60 years old;
- Meet the diagnostic criteria for dry eye in the International Society of Tears and Ocular Surface (TFOS) Dry Eye Symposium (DEWS) II ;
- 1/3 or more of the meibomian gland openings are blocked or the secretion characteristics of the meibomian gland are abnormal;
- The best corrected visual acuity for each eye is ≥ 0.5;
- Eye pressure (IOP) ≥ 5mmHg and ≤ 21mmHg per eye;
- Women with reproductive potential agree to use reliable contraceptive methods during the study period;
- Willing and able to complete all planned research visits and follow the guidance of the researchers.
Exclusion Criteria:
- Contact lens use: Having used contact lenses within 14 days prior to the screening visit, or refusing to commit to discontinuing contact lens use during the study period (within the next 2 months);
- Had undergone corneal refractive surgery (e.g., LASIK/SMILE), other corneal surgeries, cataract surgery, anti-glaucoma surgery, or fundoscopic surgery within 12 months prior to enrollment screening;
- Participation in other medical studies within 3 months prior to enrollment screening;
Presence of any of the following active ocular diseases at present or within 3 months prior to screening: I) Acute allergic conjunctivitis; II) Infection (by bacteria, viruses, fungi, etc.); III) Inflammation (e.g., keratitis, retinitis).
Meningitis, choroiditis, uveitis, scleritis, etc.;
- Eyelid abnormalities affecting eyelid function (such as ptosis, blepharospasm, entropion, ectropion, etc.);
- Extensive ocular surface scars or conditions that may compromise ocular surface integrity (e.g., Stevens-Johnson syndrome, history of chemical burns, persistent corneal epithelial defects, history of ocular trauma, etc.);
- Currently or previously diagnosed with glaucoma, or undergoing treatment with anti-glaucoma medications;
- Has used any of the following ocular medications within the past 1 month: immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or perfluorohexyloctane;
- Has received any of the following non-pharmacological treatments for dry eye within the past month: meibomian gland massage, deep eyelid margin cleansing, intense pulsed light therapy, or thermal pulsation therapy;
- During pregnancy or lactation;
- Neurological or psychiatric disorders (moderate to severe anxiety, depression, and sleep disorders);
- Uncontrolled ocular or systemic diseases;
- History of epilepsy;
- The investigator determines that the subject is not suitable for participation in this study.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: glass rod group
Implement glass rod assisted eyelid massage for a total of 4 times
|
The participants of control group receive sodium hyaluronate eye drops 4 times a day for 8 weeks, and receive glass rod assisted eyelid massage based on the group standard of "Meibomian gland massage operation procedure" (T/GDPMAA003-2023) every 2 weeks, for a total of 4 times.
Follow up evaluations will be conducted at weeks 4 and 8
|
|
Experimental: eyelid support plate group
Implement eyelid support plate assisted eyelid massage for a total of 4 times.
|
The participants of experimental group receive sodium hyaluronate eye drops in both eyes four times a day for 8 weeks, and receive eyelid support plate assisted eyelid massage based on the group standard of Meibomian gland massage procedure (T/GDPMAA003-2023) every two weeks for a total of four times.
Follow up evaluations will be conducted at weeks 4 and 8.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean change from baseline in Ocular Surface Disease Index (OSDI) score at week 8
Zeitfenster: Baseline, week 4, week 8
|
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
|
Baseline, week 4, week 8
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in first non-invasive tear film break time
Zeitfenster: Baseline, week 4, week 8
|
The time (in seconds) from the blink that evenly distributed the fluorescein to the appearance of the first tear breakup was recorded.
First non-invasive tear film rupture time (NIBUTf) was measured using an ocular surface analyzer (Keratography 5M, Oculus, Germany),
|
Baseline, week 4, week 8
|
|
proportion of Ocular Surface Disease Index (OSDI) scores showing a change ≥10 points from baseline at week 8
Zeitfenster: Baseline, week 4, week 8
|
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
|
Baseline, week 4, week 8
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Average operating time of eyelid massage (min)
Zeitfenster: Baseline, week 2, week 4, week 6
|
Record the operating time of each eyelid massage treatment in two groups (after completing surface anesthesia, from the start of eyelid massage to the completion of squeezing the upper and lower eyelids of both eyes, each eyelid is squeezed twice), timed by the same timer, and after the timer is over, the operating time (min) is recorded after verification by two researchers.
|
Baseline, week 2, week 4, week 6
|
|
change in non-invasive lacrimal height measurement(NITMH)
Zeitfenster: Baseline, week 4, week 8
|
Non-invasive lacrimal height measurement(NITMH)(mm) using an ocular surface analyzer (Keratography 5M, Oculus, Germany)
|
Baseline, week 4, week 8
|
|
Change in meibomian gland absence status
Zeitfenster: Baseline, week 4, week 8
|
Measurement of meibomian gland deficiency using an ocular surface analyzer (Keratography 5M, Oculus, Germany).
Grading criteria for meibomian gland deficiency: 0 points (normal)=no meibomian gland deficiency, 1 point (mild)=meibomian gland deficiency ratio less than 1/3, 2 points (moderate)=meibomian gland deficiency ratio between 1/3 and 2/3, 3 points (severe)=meibomian gland deficiency ratio greater than 2/3.
Determine the extent and severity of meibomian gland deficiency, calculate the sum of upper and lower eyelid grading scores for each eye, with a total score range of 0-6 points.
|
Baseline, week 4, week 8
|
|
Change in lipid layer thickness (LLT)
Zeitfenster: Baseline, week 4, week 8
|
Evaluation of lipid layer yhickness (LLT)(nm) using LipiView
|
Baseline, week 4, week 8
|
|
Change in partial blink frequency
Zeitfenster: Baseline, week 4, week 8
|
Evaluation of partial blink frequency (%) using LipiView.
|
Baseline, week 4, week 8
|
|
Changes in Meibomian gland discharge ability score
Zeitfenster: Baseline, week 4, week 8
|
Apply force to the eyeball within the range of 5 meibomian gland openings outside and in the center of the lower eyelid eyelash line, and observe the number of meibomian gland openings that can discharge meibomian gland secretions.
Grading criteria: 0 points (normal)=all 5 meibomian gland openings excrete secretions, 1 point (mild)=3 or 4 meibomian gland openings excrete secretions, 2 points (moderate)=1 or 2 meibomian gland openings excrete secretions, 3 points (severe)=no meibomian gland openings excrete secretions,The higher the score, the worse the discharge ability.
|
Baseline, week 4, week 8
|
|
Change in score of meibomian gland secretions
Zeitfenster: Baseline, week 4, week 8
|
Scoring by operator based on secretion characteristics.
Grading criteria:0 points (normal)=clear and transparent liquid secretion,1 point (mild)=cloudy liquid secretion,2 points (moderate)=cloudy granular secretion,3 points (severe)=thick and toothpaste like secretion.The higher the score, the worse the quality of the secretion
|
Baseline, week 4, week 8
|
|
comfort scores for four sessions of eyelid massage in two groups
Zeitfenster: Baseline, week 2, week 4, week 6
|
Use the Visual Analog Scale (VAS) to score the comfort of the operation.The scale is mainly composed of a 100mm straight line, with one end representing "completely painless" and the other end representing "the most severe pain imaginable" or "extreme pain".
The score range is from 0 to 100, where 0 represents complete painlessness and 100 represents the most severe pain experienced by the patient.
Patients will be asked to mark the corresponding position on this line (using an "X") to represent the intensity of pain they experienced at that time.
Within 1 minute after each operation, have participants mark the corresponding position on the scale to indicate the intensity of their pain at that time, and promptly record each result.
|
Baseline, week 2, week 4, week 6
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Juli 2026
Primärer Abschluss (Geschätzt)
1. Juli 2027
Studienabschluss (Geschätzt)
1. September 2027
Studienanmeldedaten
Zuerst eingereicht
2. Juni 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
2. Juni 2026
Zuerst gepostet (Tatsächlich)
8. Juni 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
11. Juni 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
8. Juni 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026KYPJ065
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .